期刊文献+

微量法测定人免疫球蛋白制剂Fc段生物学活性 被引量:1

Micro-determination on activating complement in detecting biological properties of Fc fragment of IVIG
下载PDF
导出
摘要 目的通过改良《中国药典》收录的人免疫球蛋白Fc段生物学活性测定法,建立1种适用于酶标仪的高效检测方法。方法本文对《中国药典》收录(通则3514)的人免疫球蛋白FC段生物学活性测定方法,在敏化过程、样品处理及动力曲线参数上进行了调整,并同时采用Origin软件对溶血反应动力学曲线进行了拟合计算结果,使检测方法更适合于采用酶标板检测,通过对比标准品和供试品溶血反应动力学曲线计算人免疫球蛋白Fc段功能活性。结果本方法检测结果稳定,重复性和中间精密度RSD约为10%。检测效率大幅提升,采用96孔酶标板,最高可同时进行30批样品检测(较药典紫外分光光度法)。结论本方法测定人免疫球蛋白制剂Fc段功能活性的稳定性好,检测效率高,可用于人免疫球蛋白制剂中Fc段功能活性检测。 Objective To improve method for determinating of biological potency of IgG Fc fragment in Chinese Pharmacopoeia and establish a method which is suitable for enzyme-labeled instrument.Methods The biological properties of FC fragment of IVIG in Chinese Pharmacopiea(General 3514)was adjusted,including sensitization process,sample treatment and dynamic curve parameters.Meanwhile,the kinetic curve of hemolysis was fitted with Origin,which made the method more suitable for enzyme plate.The biological properties of Fc fragment of IVIG was calculated by kinetics curve reaction of reference and sample.Results The method are stable,the RSD of repeatability and intermediate is 10%,also with significant improvement in efficiency.Conclusion The detection of properties of Fc fragment of IVIG is stable and efficient,it can be used for properties of Fc fragment of IVIG.
作者 陆婷婷 章俊 孙玉忠 周顺波 王蕴红 丁亚凌 LU Tingting;ZHANG Jun;SUN Yuzhong;ZHOU Shunbo;WANG Yunhong;DING Yaling(Chengdu Rongsheng Pharmaceuticals Co.,LTD,ChengDu 610041,China)
出处 《中国输血杂志》 CAS 2021年第7期713-715,共3页 Chinese Journal of Blood Transfusion
关键词 Fc段功能活性 人免疫球蛋白 IGG properties of Fc fragment IVIG IgG
  • 相关文献

参考文献4

二级参考文献32

  • 1刘欣,吴竞生,孙萍,朱薇波,蔡晓燕,郑昌成,王兴兵,杨会志,韩永胜.基因重组人凝血因子Ⅷ在中国人血友病A患者中使用的研究[J].血栓与止血学,2007,13(2):57-59. 被引量:3
  • 2[1]TARANTINO MD,COLLINS PW,et al.Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method:pharmacokinetics,efficacy,and safety in previously treated patients with haemophilia A[J].Haemophilia,2004,10(5):428-437. 被引量:1
  • 3[2]J.SHI,Y.ZHAO,J.WU,et al.Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China[J].Haemophilia,2007,13:351-356. 被引量:1
  • 4[3]ABSHIRE TC,BRACKMANN HH,SCHARRER I et al.Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group[J].Thromb Haemost,2000,83:811-816. 被引量:1
  • 5[4]KREUZ W,ESCURIOLA ETTINGSHAUSEN C,FUNK M et al.Prevention of joint damage in hemophilic children with early prophylaxis[J].Orthopade,1999,28:341-346. 被引量:1
  • 6[5]YOSHIOKA A,SHIMA M,FUKUTAKE K,et al.Safety and efficacy of a new recombinant FⅧ formulated with sucrose (rFⅧ-FS) in patients with haemophilia A:a long-term,multicentre clinical study in Japan[J].Haemophilia,2001,7 (3);242-249. 被引量:1
  • 7[6]YOSHIOKA A,FUKUTAKE K,et al.Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A:descriptive meta-analysis of post-marketing study data[J].Int J Hematol,2006,84(2):158-165. 被引量:1
  • 8[8]MEEKS SL,JOSEPHSON CD,et al.Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates[J].Curr Opin Hematol,2006,13(6):457-461. 被引量:1
  • 9[9]SEREMETIS S,LUSHER JM,ABILDGAARD CF,et al.Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A:conclusions of a 5-year study of home therapy[J].Haemophilia,1999,5(1):9-16. 被引量:1
  • 10[10]GOUDEMAND J,LAURIAN Y,CALVEZ T,et al.Risk of inhibitors in haemophilia and the type of factor replacement[J].Curr Opin Hematol,2006,13(5):316-322. 被引量:1

共引文献12

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部